> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Insulet Authorizes $1 Billion Buyback, Plans $400 Million Of It In Fourth Quarter
- URL: https://www.bullished.co/insulet-authorizes-1-billion-buyback-plans-400-million-of-it-in-fourth-quarter-7a9ae8c4/
- Published: 2026-11-04T12:29:31.000Z
- Updated: 2026-11-04T12:29:31.000Z
- Description: The Omnipod maker also raised its adjusted operating margin outlook after third-quarter net income reached $141.1 million.
- Author: Matteo Parrino
- Tags: Earnings, PODD, Industry: Healthcare

Insulet, which makes the tubeless Omnipod insulin delivery system, authorized a [$1 billion share buyback](https://www.sec.gov/Archives/edgar/data/0001145197/000114519726000190/podd-20261104.htm?ref=bullished.co) running through December 31, 2028, and plans to spend about $400 million of it in the fourth quarter, using existing cash. The company announced it Wednesday alongside third-quarter results that showed revenue up 19.2% to [$842.0 million](https://www.sec.gov/Archives/edgar/data/0001145197/000114519726000190/podd2026-09x30ex991.htm?ref=bullished.co).

## Revenue just above guidance

Revenue grew 19.6% in constant currency, slightly above the top of the company's 17.5% to 19.5% guidance range. U.S. Omnipod revenue rose 14.7% to $570.4 million, while international Omnipod revenue climbed 31.7% to $266.2 million, or 33.0% in constant currency.

Net income was $141.1 million, or $2.03 per diluted share, against $87.6 million, or $1.24, a year earlier. Operating income was $189.8 million, or 22.5% of revenue. On an adjusted basis, earnings were $1.99 per share, up 59.9%, and adjusted operating margin was 22.0% of revenue, up 490 basis points (4.9 percentage points) from a year earlier.

CEO Ashley McEvoy said the team "delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion."

## Guidance and the buyback

Insulet now expects adjusted operating margin to expand about 150 basis points this year, up from about 100 basis points in its August outlook. It narrowed total constant-currency revenue growth to 21% to 22%, from 20% to 22%, and kept its forecast of adjusted earnings-per-share growth above 30%.

The board approved the repurchase on October 30\. The program adds to earlier authorizations, does not obligate the company to buy shares, and can be modified or suspended at any time. Cash and equivalents stood at $584.4 million on September 30, down from $716.1 million at the end of 2025.

Free cash flow for the first nine months was $211.7 million, down from $329.5 million a year earlier, as capital spending rose to $113.9 million from $56.5 million.

## What Insulet sells

Insulet develops and sells Omnipod, a small disposable Pod worn on the body that delivers insulin without tubing. Omnipod 5 adds an automated dosing algorithm that works with glucose monitors. In the quarter, the company said it expanded Abbott's FreeStyle Libre 3 Plus integration across several European countries and Australia, and completed enrollment in two clinical trials, including one supporting Omnipod 6.

Insulet held its earnings call at 8:00 a.m. ET Wednesday; the pace of the planned $400 million in fourth-quarter repurchases is the next measure of how it uses that cash.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — INSULET CORP (PODD)](https://www.sec.gov/Archives/edgar/data/0001145197/000114519726000190/podd-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit podd2026-09x30ex991.htm — INSULET CORP 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001145197/000114519726000190/podd2026-09x30ex991.htm?ref=bullished.co) — SEC EDGAR